Dunn succeeds Edwin Hendrick, who resigned to pursue other endeavors, the San Diego-based company said in a statement Friday.
She has served as Biocept's vice president of commercial operations since October 2018. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (now Decipher Biosciences), PLUS Diagnostics (now Inform Diagnostics) and Genoptix.
Dunn holds an MA in education from Stanford University, and MS in Biology and BS in Biochemistry and Cell Biology from the University of California, San Diego.
Her promotion comes as Biocept advances the usage of its flagship Target Selector technology platform, which collects and analyzes molecular markers linked to tumors in circulating tumor cells as well as plasma to identify cancer mutations. The assays detect lung, breast, gastric, colorectal and prostate cancers as well as melanoma.
"Cory has done a fantastic job over the past several years in expanding our Target Selector strategy into urology and oncology, and we are delighted that she will head our commercial operations," said CEO Michael Nall.
"The entire team is united behind Cory's sales and marketing leadership and we look forward to providing updates on our commercial progress. I want to thank Edwin Hendrick for his leadership and dedication to Biocept and we wish him all the best in his future endeavors."
Dunn added: "I look forward to taking on this new challenge and am enthusiastic about working with the commercial team to expand Biocept's reach and the universe of patients who can benefit from our Target Selector testing."
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham